Gilead is withdrawing the accelerated approval for its blockbuster antibody-drug conjugate Trodelvy for bladder cancer after ...
Gilead Sciences is pulling its blockbuster breast-cancer drug Trodelvy from use in certain patients with bladder cancer following the failure of a confirmatory study. Gilead on Friday said it ...
Trodelvy (sacituzumab govitecan-hziy) is a brand-name IV infusion prescribed for certain cancers in adults. As with other drugs, Trodelvy can cause side effects, such as diarrhea, hair loss ...
Trodelvy (sacituzumab govitecan-hziy) is a prescription drug used to treat certain breast and bladder cancers. Scientists have studied the success rate of Trodelvy and found it to be effective in ...
7-10, 2024 in San Diego, Calif. Data to be highlighted across three oral presentations include: initial results from two cohorts of the EVOKE-02 study of Trodelvy ® (sacituzumab govitecan-hziy ...